Dual Inhibitors of COX-2 and Soluble Epoxide Hydrolase (sEH)
DOI:
https://doi.org/10.12970/2308-8044.2013.01.02.5Keywords:
AUDA, (1, 5)-Diarylpyrazole derivatives, Hypertension, N-Acyl, sEH inhibition, Urea, etc.Abstract
A series of novel Dual Inhibitors of COX-2 and sEH containing an N-urea substituted pyrazole as a lead for sEH inhibition have been synthesized and screened as novel analogues to reduce blood pressure elevation by acting as sEH inhibitors. The synthesized compounds having varying degrees of selectivity towards the sEH enzymes. Particularly compounds 6g and 6i emerged as the most potent sEH inhibitor displaying IC50 values of 0.114 ± 0.014 µM and 0.120 ± 0.03 µM for in-vitro sEH inhibition and the selectivity for COX-2 enzyme pave the way for discovery of novel Dual Inhibitors.
References
Vane JR. The mode of action of aspirin and similar compounds. J Allergy Clin Immunol 1976; 58: 691-12. http://dx.doi.org/10.1016/0091-6749(76)90181-0
Rao BN, Synthesis of 1,5-Diarylpyrazoles as Potential COX-2 Inhibitors with Nitric Oxide Releasing Ability. Lett Drug Design Discov 2013; 10: 594-603. http://dx.doi.org/10.2174/1570180811310070006
Moncada S, Ferreira SH, Vane JR, Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature 1973; 246: 217-19. http://dx.doi.org/10.1038/246217a0
Tamblyn R, Berkson L, Dauphinee WD, Gayton D, Grad RA, et al. Unnecessary prescribing of NSAIDs and the management of NSAID related gastropathy in medical practice. Ann Intern Med 1997; 127: 429-38. http://dx.doi.org/10.7326/0003-4819-127-6-199709150-00003
Masferrer JL, Zweifel BS, Seibert K, Needleman P. Selective regulation of cellular cyclooxygenase by dexamethasone and endotoxin in mice. J Clin Invest 1990; 86: 1375-79. http://dx.doi.org/10.1172/JCI114850
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of amitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991; 88: 2692-96. http://dx.doi.org/10.1073/pnas.88.7.2692
Kujubu DA, Herschman HR. Dexamethasone inhibits mitogen induction of the TIS10 prostaglandin synthase/cyclooxygenase gene. J Biol Chem 1992; 267: 7991-94.
Meade EA, Smith WL, DeWitt D L. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. J Biol Chem 1993; 268: 6610-14.
Vane JR, Bakhle YS, Botting RM. Cyclooxygenase 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120. http://dx.doi.org/10.1146/annurev.pharmtox.38.1.97
Newman JW, Morisseau C, Hammock BD. Epoxide hydrolases: Their roles and interactions with lipid metabolism. Prog Lipid Res 2005; 44: 1-51. http://dx.doi.org/10.1016/j.plipres.2004.10.001
Morisseau C, Hammock BD. Epoxide hydrolases: Mechanisms, inhibitor designs, and biological roles. Annu Rev Pharmacol Toxicol 2005; 45: 311-33. http://dx.doi.org/10.1146/annurev.pharmtox.45.120403.095920
Fretland AJ, Omiecinski CJ. Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 2000; 129: 41-59. http://dx.doi.org/10.1016/S0009-2797(00)00197-6
Xiang F. Recent Patents on Cardiovascular Drug Discovery. 2006; 1: 1-7.
Falck JR, Reddy LM, Reddy YK. 11, 12-epoxyeicosatrienoic acid (11, 12-EET): structural determinants for inhibition of TNF-alpha induced VCAM-1 expression. Bioorg Med Chem Lett 2003; 13: 4011-14. http://dx.doi.org/10.1016/j.bmcl.2003.08.060
Node K, Ruan XL, Dai J. Activation of G as mediates induction of tissue-type plasminogen activator gene transcription by epoxyeicosatrienoicacids. J Biol Chem 2001; 276: 15983-89. http://dx.doi.org/10.1074/jbc.M100439200
Node K, Huo Y, Ruan X. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-79. http://dx.doi.org/10.1126/science.285.5431.1276
Fitzpatrick FA, Ennis MD, Baze ME. Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 1986; 261: 15334-38.
Iber H, Chen Q, Cheng PY. Suppression of CYP2C11 gene transcription by interleukin-1 mediated by NF-kappaB binding at the transcription start site. Arch Biochem Biophys 2000; 377: 187-94. http://dx.doi.org/10.1006/abbi.2000.1772
Kessler P, Popp R, Busse R. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation 1999; 99: 1878-84. http://dx.doi.org/10.1161/01.CIR.99.14.1878
Wallace JL, Ignarro LJ, Fiorucci S. Potential cardioprotective actions of NO-releasing aspirin. Nat Rev Drug Discov 2002; 1: 375-82. http://dx.doi.org/10.1038/nrd794
Dailey LA, Imming P. 12-Lipoxygenase: Classification, possible therapeutic benefits from inhibition and inhibitors. Curr Med Chem 1999; 6: 389-98.
Zalewski A, Nelson JJ, Heg JJ, Macphee C. Lp-PLA22: A new kid on the block. Clin Chem 2006; 52: 1645-49. http://dx.doi.org/10.1373/clinchem.2006.070672
Samuelsson B, Morgenstern R, Jakobsson PJ. Membrane prostaglandin E synthase-1: A novel therapeutic target. Pharmacol Rev 2007; 59: 207-24. http://dx.doi.org/10.1124/pr.59.3.1
Friesen RW, Mancini JA. Microsomal prostaglandin E synthase-1 (mPGES-1): A novel antiinflammatory therapeutic target. J Med Chem 2008; 51: 4059-67. http://dx.doi.org/10.1021/jm800197b
Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein protein interfaces. Nature 2007; 450: 1001-1009. http://dx.doi.org/10.1038/nature06526
Taylor PC. The future of TNF-α antagonism. Future Rheumatol 2007; 2: 233-36. http://dx.doi.org/10.2217/17460816.2.3.233
Chan DS, Lee HM, Yang F, Che CM, Wong CCL, Abagyan R, et al. Structure-based discovery of natural-product-like TNF-a inhibitors. Angew Chem Int Ed 2010; 49: 2860-64. http://dx.doi.org/10.1002/anie.200907360
Smith AS, Oslob JD, Flanagan WM, Braisted AC, Whitty A, Cancilla MT, et al. Small-molecule inhibition of TNF-alpha. Science 2005; 310: 1022-25. http://dx.doi.org/10.1126/science.1116304
Magda AA, El Sayed, Naglaa I, Abdel Aziz, Alaa AM, Abdel Aziz, et al. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study. Bioorg Med Chem 2011; 19: 3416-24. http://dx.doi.org/10.1016/j.bmc.2011.04.027
Hwang S H, Wagner K M, Morisseau C, Liu J Y, Dong H, Aaron T, Wecksler A T, Hammock B D. Synthesis and Structure Activity Relationship Studies of Urea-Containing Pyrazoles as Dual Inhibitors of Cyclooxygenase-2 and Soluble Epoxide Hydrolase. J Med Chem 2011; 54: 3037–3050. http://dx.doi.org/10.1021/jm2001376
